JP2019023243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019023243A5 JP2019023243A5 JP2018218127A JP2018218127A JP2019023243A5 JP 2019023243 A5 JP2019023243 A5 JP 2019023243A5 JP 2018218127 A JP2018218127 A JP 2018218127A JP 2018218127 A JP2018218127 A JP 2018218127A JP 2019023243 A5 JP2019023243 A5 JP 2019023243A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- phosphatidyl
- liposome
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000002502 liposome Substances 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 6
- 150000002632 lipids Chemical group 0.000 claims 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 4
- 150000003904 phospholipids Chemical class 0.000 claims 4
- 150000003431 steroids Chemical class 0.000 claims 4
- 230000001225 therapeutic Effects 0.000 claims 4
- ZAKBPRIDLSBYQQ-VHSXEESVSA-N 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OC[C@@H](O)CO ZAKBPRIDLSBYQQ-VHSXEESVSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 2
- LDGWQMRUWMSZIU-UHFFFAOYSA-M 2,3-bis(octadec-9-enoxy)propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCC=CCCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCCC=CCCCCCCCC LDGWQMRUWMSZIU-UHFFFAOYSA-M 0.000 claims 2
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims 2
- 229940107161 Cholesterol Drugs 0.000 claims 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N Dipalmitoylphosphatidylcholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 2
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 claims 2
- 229940067631 Phospholipids Drugs 0.000 claims 2
- FVJZSBGHRPJMMA-IOLBBIBUSA-N [(2R)-2,3-bis(octadecanoyloxy)propoxy][(2S)-2,3-dihydroxypropoxy]phosphinic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- -1 cationic lipid Chemical class 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 239000000411 inducer Substances 0.000 claims 2
- 150000008103 phosphatidic acids Chemical class 0.000 claims 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 2
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000004797 therapeutic response Effects 0.000 claims 1
Claims (20)
- 少なくとも1つの脂質、少なくとも1つの治療剤および少なくとも1つの診断剤ならびにその組み合わせを含有する治療リポソームであって、該治療剤が抗がん剤または細胞傷害剤である、治療リポソームと;
少なくとも1つの脂質および少なくとも1つの非イオン性誘発剤を含有する攻撃リポソームと
を含む医薬組成物であって、該医薬組成物は、被験体において治療応答に影響を与えるのに十分な用量で該被験体に投与されることを特徴とする、医薬組成物。 - 前記治療リポソームが、リン脂質、ステロイドおよびカチオン性脂質からなる群より選択される少なくとも1つの脂質を含有する、請求項1に記載の医薬組成物。
- 前記リン脂質が、ホスファチジルコリン、ホスファチジルグリセロール、ホスファチジルエタノールアミン、ホスファチジルセリン、ホスファチジルイノシトール、およびホスファチジン酸からなる群より選択される、請求項2に記載の医薬組成物。
- 前記ホスファチジルコリンが、ジステアロイルホスファチジルコリン(DSPC)である、請求項3に記載の医薬組成物。
- 前記ホスファチジルグリセロールが、ジステアロイルホスファチジルグリセロール(DSPG)である、請求項3に記載の医薬組成物。
- 前記ホスファチジルエタノールアミンが、DSPE−PEG(2000)である、請求項3に記載の医薬組成物。
- 前記ステロイドがコレステロールである、請求項2に記載の医薬組成物。
- 前記カチオン性脂質が、N−(1−(2,3−ジオレオイルオキシ)プロピル)−N,N,N−トリメチルアンモニウムクロリド(DOTAP)である、請求項2に記載の医薬組成物。
- 前記攻撃リポソームが、第2のリポソーム、ミセル、およびその混合物からなる群より選択される少なくとも1つの脂質を含有する、請求項1に記載の医薬組成物。
- 前記第2のリポソームが、リン脂質、ステロイド、およびカチオン性脂質からなる群より選択される1または複数の脂質を含有する、請求項9に記載の医薬組成物。
- 前記リン脂質が、ホスファチジルコリン、ホスファチジルグリセロール、ホスファチジルエタノールアミン、ホスファチジルセリン、ホスファチジルイノシトール、およびホスファチジン酸からなる群より選択される、請求項10に記載の医薬組成物。
- 前記ホスファチジルコリンが、ジパルミトイルホスファチジルコリン(DPPC)である、請求項11に記載の医薬組成物。
- 前記ステロイドがコレステロールである、請求項10に記載の医薬組成物。
- 前記カチオン性脂質が、N−(1−(2,3−ジオレオイルオキシ)プロピル)−N,N,N−トリメチルアンモニウムクロリド(DOTAP)である、請求項10に記載の医薬組成物。
- 前記非イオン性誘発剤が、D−α−トコフェリルポリエチレングリコールスクシネート(TPGS)である、請求項1に記載の医薬組成物。
- 前記組成物が少なくとも1つの標的化剤を含有する、請求項1に記載の医薬組成物。
- 前記攻撃リポソームの投与が、前記治療リポソームからの前記治療剤の放出を、該攻撃リポソームを用いずに該治療リポソームを投与するのと比較して、少なくとも3倍、10倍または25倍増加させる、請求項1に記載の医薬組成物。
- 前記治療剤が、前記リポソームの二重層内に包埋されている、請求項1に記載の医薬組成物。
- 前記治療剤が、前記リポソームの水性コア内に封入されている、請求項1に記載の医薬組成物。
- 前記治療剤が、前記リポソームの外部に係留されている、請求項1に記載の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161553786P | 2011-10-31 | 2011-10-31 | |
US61/553,786 | 2011-10-31 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017044663A Division JP6549172B2 (ja) | 2011-10-31 | 2017-03-09 | がん治療用組合せリポソーム組成物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019088222A Division JP2019123753A (ja) | 2011-10-31 | 2019-05-08 | がん治療用組合せリポソーム組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019023243A JP2019023243A (ja) | 2019-02-14 |
JP2019023243A5 true JP2019023243A5 (ja) | 2019-06-13 |
Family
ID=47146747
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014539143A Expired - Fee Related JP6143767B2 (ja) | 2011-10-31 | 2012-10-31 | がん治療用組合せリポソーム組成物 |
JP2017044663A Expired - Fee Related JP6549172B2 (ja) | 2011-10-31 | 2017-03-09 | がん治療用組合せリポソーム組成物 |
JP2018218127A Pending JP2019023243A (ja) | 2011-10-31 | 2018-11-21 | がん治療用組合せリポソーム組成物 |
JP2019088222A Pending JP2019123753A (ja) | 2011-10-31 | 2019-05-08 | がん治療用組合せリポソーム組成物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014539143A Expired - Fee Related JP6143767B2 (ja) | 2011-10-31 | 2012-10-31 | がん治療用組合せリポソーム組成物 |
JP2017044663A Expired - Fee Related JP6549172B2 (ja) | 2011-10-31 | 2017-03-09 | がん治療用組合せリポソーム組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019088222A Pending JP2019123753A (ja) | 2011-10-31 | 2019-05-08 | がん治療用組合せリポソーム組成物 |
Country Status (12)
Country | Link |
---|---|
US (4) | US9370489B2 (ja) |
EP (2) | EP3424564A1 (ja) |
JP (4) | JP6143767B2 (ja) |
KR (1) | KR20140097215A (ja) |
CN (1) | CN104023793B (ja) |
BR (1) | BR112014010291A2 (ja) |
CA (1) | CA2852564A1 (ja) |
ES (1) | ES2694154T3 (ja) |
IL (2) | IL232344B (ja) |
MX (1) | MX360391B (ja) |
RU (1) | RU2640934C2 (ja) |
WO (1) | WO2013066903A1 (ja) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2768444A1 (en) * | 2009-07-17 | 2011-01-20 | Rigshospitalet | Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines |
CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CN104531812A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RU2707251C2 (ru) | 2011-10-03 | 2019-11-25 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
EP2833892A4 (en) | 2012-04-02 | 2016-07-20 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
EP3757570B1 (en) * | 2013-03-15 | 2023-10-11 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
JP2014227338A (ja) * | 2013-05-17 | 2014-12-08 | キヤノン株式会社 | インドシアニングリーン含有粒子およびその製造方法 |
WO2015013579A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Compositions to improve the therapeutic benefit of bisantrene |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
PL3138555T3 (pl) | 2014-04-30 | 2021-04-06 | Fujifilm Corporation | Kompozycja liposomowa i sposób jej wytwarzania |
WO2016131006A1 (en) * | 2015-02-13 | 2016-08-18 | Orient Pharma Inc. | Compositions and methods of tumor treatment utilizing nanoparticles |
CN107530283A (zh) | 2015-03-03 | 2018-01-02 | 奎尔波特股份有限公司 | 组合脂质体药物制剂 |
JP2018507227A (ja) | 2015-03-03 | 2018-03-15 | キュアポート インコーポレイテッド | 二薬搭載リポソーム医薬製剤 |
JP2018510859A (ja) * | 2015-03-17 | 2018-04-19 | レオン−ナノドラッグズ ゲーエムベーハー | 安定化されたボロン酸化合物を含むナノ粒子 |
US10918599B2 (en) * | 2015-04-02 | 2021-02-16 | The Research Foundation For The State University Of New York | Serum-stable compositions and methods for light-triggered release of materials |
HRP20220156T1 (hr) | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
ES2869283T3 (es) * | 2015-11-02 | 2021-10-25 | Fujifilm Corp | Agente terapéutico antitumoral que contiene composición de liposoma de gemcitabina y kit |
WO2017087685A1 (en) * | 2015-11-20 | 2017-05-26 | The Regents Of The University Of California | Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery |
JP7080172B2 (ja) | 2015-12-10 | 2022-06-03 | モデルナティエックス インコーポレイテッド | 治療薬の送達のための組成物及び方法 |
WO2017104840A1 (ja) * | 2015-12-18 | 2017-06-22 | メディギア・インターナショナル株式会社 | 生体分解性腫瘍封止剤 |
DK3394030T3 (da) | 2015-12-22 | 2022-03-28 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af midler |
KR101630397B1 (ko) * | 2015-12-31 | 2016-06-24 | 한국과학기술원 | 항암제-인도시아닌 그린-리포좀 복합체를 포함하는 암 치료용 조성물 |
EP3416623B1 (en) | 2016-02-15 | 2021-08-11 | University of Georgia Research Foundation, Inc. | Ipa-3-loaded liposomes and methods of use thereof |
JP7195147B2 (ja) | 2016-05-16 | 2022-12-23 | アクセス ツー アドバンスト ヘルス インスティチュート | Peg化リポソームおよび使用方法 |
US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
CN106474057A (zh) * | 2016-12-02 | 2017-03-08 | 中国药科大学 | 一种奥沙利铂热敏长循环脂质体的蔗糖溶液制剂及其制备方法 |
BR112019014718A2 (pt) * | 2017-01-18 | 2020-03-10 | Temasek Life Sciences Laboratory Limited | Lipossomas hiperestabilizados aumentam o direcio-namento de células mitóticas |
AU2018234814B2 (en) | 2017-03-15 | 2022-06-30 | Modernatx, Inc. | Crystal forms of amino lipids |
KR20190132405A (ko) | 2017-03-15 | 2019-11-27 | 모더나티엑스, 인크. | 치료제의 세포내 전달을 위한 화합물 및 조성물 |
AU2018234828A1 (en) | 2017-03-15 | 2019-09-19 | Modernatx, Inc. | Lipid nanoparticle formulation |
MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
US10925831B2 (en) * | 2017-08-28 | 2021-02-23 | Wake Forest University | Liposomal formulations of platinum-acridine anticancer agents and methods thereof |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
WO2019084290A1 (en) * | 2017-10-25 | 2019-05-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF PHARMACEUTICAL AGENTS |
US10606661B2 (en) * | 2017-12-15 | 2020-03-31 | Rubrik, Inc. | On-demand provisioning of customized developer environments |
EP3890775A1 (en) * | 2018-12-06 | 2021-10-13 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
RU2706427C1 (ru) * | 2018-12-27 | 2019-11-19 | Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" | Способ лечения онкологических заболеваний с помощью инъекций лекарственного препарата |
JP7253735B2 (ja) | 2019-07-02 | 2023-04-07 | パナソニックIpマネジメント株式会社 | 通過可否判定装置、通過管理システム、通過可否判定方法、及び、コンピュータプログラム |
EP4031524A1 (en) | 2019-09-19 | 2022-07-27 | ModernaTX, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
US20220364139A1 (en) * | 2019-09-24 | 2022-11-17 | Pataigin, Llc | Methods for determining growth and response |
CN110571005B (zh) * | 2019-09-27 | 2021-01-01 | 广西科技大学 | 一种固定化金属离子-磁性脂质体及其制备方法和应用 |
WO2022038605A1 (en) * | 2020-08-20 | 2022-02-24 | Bionanosim (Bns) Ltd | Lipid delivery systems for delivery of oxaliplatin palmitate acetate |
KR102560135B1 (ko) | 2020-12-04 | 2023-07-27 | 가톨릭대학교 산학협력단 | 표적 치료제의 효과적인 전달을 위한 다기능성 리포좀 조성물 |
WO2022171777A1 (en) | 2021-02-12 | 2022-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for prognosis and treating a patient suffering from cancer |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
EP4306126A1 (en) | 2021-03-08 | 2024-01-17 | Eyegene Inc. | Vaccine composition for preventing sars-cov-2 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023087A (en) * | 1986-02-10 | 1991-06-11 | Liposome Technology, Inc. | Efficient method for preparation of prolonged release liposome-based drug delivery system |
CA2252055C (en) | 1996-04-11 | 2007-01-16 | The University Of British Columbia | Fusogenic liposomes |
US6897196B1 (en) | 2001-02-07 | 2005-05-24 | The Regents Of The University Of California | pH sensitive lipids based on ortho ester linkers, composition and method |
US7273620B1 (en) | 2002-05-20 | 2007-09-25 | University Of British Columbia | Triggered release of liposomal drugs following mixing of cationic and anionic liposomes |
US7149468B2 (en) | 2002-07-25 | 2006-12-12 | The Mcgraw-Hill Companies, Inc. | Methods for improving certainty of test-taker performance determinations for assessments with open-ended items |
WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
WO2004103344A1 (en) * | 2003-05-20 | 2004-12-02 | Aronex Pharmaceuticals, Inc. | Combination chemotherapy comprising a liposomal platinum complex |
US20070248541A1 (en) * | 2003-12-01 | 2007-10-25 | Mitsubishi Pharma Corporation | Liposome |
TWI262798B (en) * | 2003-12-31 | 2006-10-01 | Ind Tech Res Inst | Liposome and drug deliver system |
US20110020434A1 (en) | 2005-09-02 | 2011-01-27 | O'halloran Thomas V | Nanoparticle arsenic-platinum compositions |
WO2007049279A2 (en) * | 2005-10-26 | 2007-05-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A liposomal combination and uses thereof |
-
2012
- 2012-10-31 EP EP18189596.2A patent/EP3424564A1/en not_active Withdrawn
- 2012-10-31 US US13/664,457 patent/US9370489B2/en not_active Expired - Fee Related
- 2012-10-31 CA CA2852564A patent/CA2852564A1/en not_active Abandoned
- 2012-10-31 RU RU2014120216A patent/RU2640934C2/ru not_active IP Right Cessation
- 2012-10-31 KR KR1020147014027A patent/KR20140097215A/ko not_active Application Discontinuation
- 2012-10-31 JP JP2014539143A patent/JP6143767B2/ja not_active Expired - Fee Related
- 2012-10-31 EP EP12783805.0A patent/EP2773426B1/en not_active Not-in-force
- 2012-10-31 WO PCT/US2012/062635 patent/WO2013066903A1/en active Application Filing
- 2012-10-31 CN CN201280064482.6A patent/CN104023793B/zh not_active Expired - Fee Related
- 2012-10-31 ES ES12783805.0T patent/ES2694154T3/es active Active
- 2012-10-31 MX MX2014004960A patent/MX360391B/es active IP Right Grant
- 2012-10-31 BR BR112014010291A patent/BR112014010291A2/pt not_active Application Discontinuation
-
2014
- 2014-04-29 IL IL232344A patent/IL232344B/en active IP Right Grant
-
2016
- 2016-05-23 US US15/162,072 patent/US9717686B2/en not_active Expired - Fee Related
-
2017
- 2017-03-09 JP JP2017044663A patent/JP6549172B2/ja not_active Expired - Fee Related
- 2017-07-28 US US15/663,472 patent/US10213385B2/en not_active Expired - Fee Related
-
2018
- 2018-04-16 IL IL258740A patent/IL258740B/en unknown
- 2018-11-21 JP JP2018218127A patent/JP2019023243A/ja active Pending
-
2019
- 2019-02-19 US US16/279,977 patent/US20190175505A1/en not_active Abandoned
- 2019-05-08 JP JP2019088222A patent/JP2019123753A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019023243A5 (ja) | ||
JP2014532665A5 (ja) | ||
Apolinário et al. | Lipid nanovesicles for biomedical applications:‘What is in a name’? | |
RU2014120216A (ru) | Комбинационные липосомальные композиции для лечения рака | |
WO2010041255A2 (en) | Liposomal systems comprising sphingomyelin | |
US20150093434A1 (en) | Liposomal compositions of glucocorticoid and glucocorticoid derivatives | |
JP2015515992A5 (ja) | ||
Nekkanti et al. | Recent advances in liposomal drug delivery: a review | |
JP2018184470A5 (ja) | ||
TW201907908A (zh) | 包含弱酸藥物之脂質體組成物及其用途 | |
JP2006509750A (ja) | リポソームグルココルチコイド | |
JP2015519383A5 (ja) | ||
JP2007529546A (ja) | 吸入によるシスプラチンの投与 | |
US20170281541A1 (en) | Liposome-based mucus-penetrating particles for mucosal delivery | |
JP3202999B2 (ja) | 肝移行性リポソーム製剤 | |
KR20150034517A (ko) | 소수성 활성 성분 및 폴리펩티드의 복합체를 포함하는 리포좀, 및 그의 용도 | |
EP1793805A1 (en) | Liposomal formulations comprising an amphipathic weak base like tempamine for treatment of neurodegenerative conditions | |
TWI767133B (zh) | 含有治療憂鬱症或焦慮症之治療劑的緩釋組合物及其用途 | |
JP2018527335A5 (ja) | ||
US9078812B2 (en) | Particulate drug carriers as desensitizing agents | |
WO2020210317A1 (en) | Immunotherapeutic nanoparticles and methods relating thereto | |
DOI et al. | Therapeutic effect of reticuloendothelial system (RES)-avoiding liposomes containing a phospholipid analogue of 5-fluorouracil, dipalmitoylphosphatidylfluorouridine, in Meth A sarcoma-bearing mice | |
WO2004087097A2 (en) | Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer | |
WO2022050369A1 (ja) | 抗菌薬を含有するリポソーム製剤 | |
US7008791B1 (en) | Liposome-entrapped DNA oral vaccines |